MK-677

What MK-677 Does

MK-677 (Ibutamoren) is an oral, non-peptide growth hormone secretagogue. It mimics the hunger hormone ghrelin by binding to the GHS-R1a receptor in the hypothalamus and pituitary, triggering sustained growth hormone release. It is not a peptide — it’s a small molecule that can be taken orally, which is its primary advantage over injectable GH peptides.

The mechanisms that matter:

• Ghrelin receptor agonism — binds the same receptor as Ipamorelin and ghrelin, stimulating GH release from the anterior pituitary. Unlike injectable GHRPs, MK-677’s oral bioavailability and long half-life (24 hours) mean once-daily dosing produces sustained GH elevation
• Sustained IGF-1 elevation — clinical studies show 40–90% increases in IGF-1 levels maintained throughout the dosing period, even after 12 months of continuous use. No tachyphylaxis (tolerance) observed
• GH pulse amplification — increases both the amplitude and frequency of GH pulses, particularly the nocturnal surge when taken before bed
• Appetite stimulation — as a ghrelin mimetic, it strongly activates hunger signaling. This is a feature for underweight populations and a side effect for body recomposition goals

MK-677 vs Injectable GH Peptides

Feature	MK-677	CJC-1295 + Ipamorelin
Route	Oral (pill/liquid)	Subcutaneous injection
Dosing frequency	Once daily	2–3x daily
GH release pattern	Sustained elevation	Pulsatile (more physiological)
IGF-1 increase	40–90%	30–60%
Hunger increase	Significant	Mild
Insulin sensitivity	Reduced with prolonged use	Minimal impact
Convenience	Very high (just swallow it)	Lower (reconstitution, injection)
Desensitization	None observed	Minimal with cycling
Human clinical data	Extensive (Phase II trials)	Moderate

Bottom line: MK-677 is the convenience choice — no needles, no reconstitution, once daily. CJC-1295 + Ipamorelin is the precision choice — cleaner pulsatile release, less hunger, less insulin impact. Many advanced users run both: injectable GH peptides on training days, MK-677 on rest days.

Dosing Protocol

Standard Protocol

Parameter	Detail
Dose	10–25 mg/day
Frequency	Once daily, oral
Best timing	30 minutes before bed
Cycle length	8–16 weeks on, 4–8 weeks off
Form	Capsule or liquid solution

Dose Tiers

Level	Dose	Best For
Low	10 mg/day	Sleep improvement, recovery, joint support, minimal side effects
Standard	15 mg/day	Balance of benefits and side effects. Good starting point for body composition
High	25 mg/day	Maximum GH/IGF-1 elevation. Best for underweight users or those prioritizing mass

Start at 10 mg. This dose provides meaningful GH elevation (~60% IGF-1 increase in studies) with manageable hunger and water retention. Increase to 25 mg only after 2+ weeks of assessing tolerance.

Timing

Before bed is strongly recommended:

1. Amplifies the natural nocturnal GH surge — the largest GH release of the day
2. Hunger spike occurs while sleeping — you don’t have to resist it
3. Many users report dramatically deeper sleep within the first few nights
4. The 24-hour half-life ensures coverage throughout the following day

Morning dosing alternative: Produces comparable GH elevation but the intense hunger in the first 2–4 hours can be challenging. If you choose morning dosing, have a high-protein meal ready.

Long-Term / Continuous Use

MK-677 does not cause pituitary desensitization. Studies up to 2 years showed sustained GH and IGF-1 elevation without efficacy loss. However:

• Insulin sensitivity degrades over time — fasting glucose typically increases 5–10 mg/dL with chronic high-dose use
• Cycling is prudent — 8–16 weeks on, 4–8 weeks off, or continuous at 10 mg with quarterly HbA1c monitoring
• Some users run 10 mg continuously year-round — the insulin impact at this dose is minimal for metabolically healthy individuals. This is a risk-tolerance decision.

Managing Side Effects

Hunger (The Big One)

MK-677’s appetite stimulation is its most impactful side effect. For body recomposition goals, this can be counterproductive. Strategies:

• Take before bed — sleep through the worst of it
• Start at 10 mg — hunger is dose-dependent. 10 mg is manageable, 25 mg can be intense
• High-protein, high-fiber meals — increases satiety. Front-load protein at dinner
• The hunger fades — most users report appetite normalization after 2–4 weeks as ghrelin receptor sensitivity adjusts
• If cutting (caloric deficit) — consider 10 mg only, or use CJC-1295/Ipamorelin instead

Water Retention

• Most noticeable in the first 2–4 weeks (face, hands, ankles)
• Reduce sodium intake to minimize
• Does not indicate fat gain — it’s intracellular water driven by GH
• Resolves within 1–2 weeks of discontinuation
• If bothersome, reduce dose to 10 mg

Lethargy / Grogginess

• Some users report morning grogginess, especially at 25 mg
• This usually resolves within 1–2 weeks as the body adjusts
• Paradoxically, sleep quality is dramatically improved — the grogginess is often from deeper sleep cycles, not poor sleep

What the Research Says

MK-677 has one of the strongest clinical evidence bases of any GH secretagogue:

Human clinical trials (extensive):

• A 2-year randomized, double-blind, placebo-controlled trial in healthy elderly adults showed 25 mg/day increased GH secretion to youthful levels, increased IGF-1 by ~40%, increased fat-free mass by 1.6 kg, and improved physical function. No pituitary desensitization was observed over 2 years. (Annals of Internal Medicine, 2008)
• A study in healthy young males showed a single 25 mg dose increased 24-hour GH secretion by 97% and IGF-1 by 55%. Effects were sustained with daily dosing. (Journal of Clinical Endocrinology & Metabolism, 1997)
• In obese males, MK-677 (25 mg/day for 8 weeks) increased GH area under the curve by 2-fold, IGF-1 by 40%, and fat-free mass by 3 kg versus placebo, with no change in visceral fat. (Journal of Clinical Endocrinology & Metabolism, 1998)

Sleep data:

• MK-677 increased REM sleep duration by 50% and Stage 4 (deep) sleep by 20% in healthy young subjects. This is one of the most consistent findings across studies and likely drives many of the subjective benefits users report.

Insulin sensitivity concern:

• The 2-year elderly study showed fasting glucose increased from ~95 to ~105 mg/dL on average, with a corresponding rise in insulin resistance markers. No subjects developed diabetes, but the trend is clear with long-term use at 25 mg.

Key practitioners:

• Derek (More Plates More Doses) covers MK-677 extensively, emphasizing the 10 mg dose for sleep and recovery with acceptable hunger
• Andrew Huberman has discussed MK-677’s effect on deep sleep and GH secretion in the context of sleep optimization

Safety

Common Side Effects

• Increased appetite — the most prominent and consistent effect. Dose-dependent. Manageable at 10 mg, intense at 25 mg.
• Water retention — mild to moderate, especially face and extremities. Resolves with discontinuation.
• Numbness/tingling — carpal tunnel-like symptoms from GH elevation. Dose-dependent.
• Morning grogginess — first 1–2 weeks, typically resolves.
• Muscle cramps — occasional, may be related to water/electrolyte shifts. Ensure adequate magnesium and potassium.
• Vivid dreams — very commonly reported. Related to increased REM sleep.

Critical Warnings

Insulin sensitivity. MK-677 raises fasting glucose and can worsen insulin resistance with chronic high-dose use. Monitor fasting glucose and HbA1c every 3 months during extended use. Cycle off if fasting glucose exceeds 100 mg/dL.

Not for diabetics. Type 2 diabetics on insulin or sulfonylureas face hypoglycemia risk from the insulin sensitivity changes. Type 1 diabetics should avoid entirely.

Not FDA-approved. MK-677 was developed by Merck but never brought to market. All human use is off-label and experimental.

Banned by WADA. Classified as a GH secretagogue under S2 prohibited substances.

Cancer precaution. Like all GH-elevating compounds, MK-677 promotes cell growth and IGF-1 signaling. Do not use with active malignancies or significant cancer risk factors.

Do Not Use If

• Type 1 or poorly controlled Type 2 diabetes
• Active cancer or tumor history
• Prediabetic or metabolic syndrome (fasting glucose > 100 mg/dL)
• Congestive heart failure (GH can worsen fluid retention)
• Pregnant or breastfeeding
• Under 18
• Subject to WADA/USADA testing

What Comes Next

MK-677 is a great entry point for GH optimization. Next steps:

• Add injectable GH peptides with the Growth Hormone Stack — CJC-1295 + Ipamorelin for pulsatile GH release on training days
• Compare all GH options in the Growth Hormone Peptides Compared guide
• Pair with healing peptides — BPC-157 (protocol) or TB-500 (protocol) for synergistic recovery
• Use the Reconstitution Calculator if adding injectable peptides to your protocol